Chondrosarcoma (CHS), also known as malignant cartilage
tumors,
is the second most common bone cancer after osteosarcoma. This tumor
is particularly chemo- and radioresistant, and the only therapeutic
alternative is surgery with wide margins. The tumor immune microenvironment
reveals an infiltration of tumor-associated macrophages (TAMs) sometimes
approaching 50% of the tumor mass, mainly differentiated into M2-like
phenotype and correlated with poor prognosis and metastasis. Thus,
macrophage-targeting therapies could have an interest in the management
of CHS. To evaluate these strategies, we propose here the development
of a three-dimensional (3D) tumoroid co-culture model between two
human CHS cell lines (JJ012 and CH2879) and a human leukemia monocytic
cell line (THP-1) in a methylcellulose matrix. These two models were
compared to the in vivo xenograft models in terms of macrophage phenotypes,
proteoglycans, MMP-9, and COX-2 expression. Finally, mifamurtide,
an immunomodulator acting on TAMs, was evaluated on the most in vitro
relevant model: 3D co-culture CH2879 model. Our results showed that
it is now possible to develop 3D models that very accurately mimic
what is found in vivo with the possibility of evaluating treatments
specific to a tumor cell component.